Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Применение пероральной формы винорелбина при метастатическом раке молочной железы – выбор в пользу качества жизни

https://doi.org/10.33667/2078-5631-2022-13-7-13

Полный текст:

Аннотация

Метастатический рак молочной железы (мРМЖ) на сегодняшний день является неизлечимой болезнью, основными целями лечения являются продление жизни, сохранение и повышение ее качества и контроль над симптомами. Современный арсенал противоопухолевых средств при выборе оптимального режима лечения позволяет руководствоваться не только показателями эффективности и безопасности, но и учитывать удобство применения препаратов. Так, пероральная форма винорелбина демонстрирует высокую противоопухолевую эффективность вне зависимости от подтипа мРМЖ и линии лечения, а также позволяет пациенту избежать серьезной токсичности и сохранять привычный образ жизни. В данном обзоре представлены результаты основных клинических исследований винорелбина, особое внимание уделено комбинациям для лечения HER2-положительного метастатического рака молочной железы. Представлен случай успешного лечения редкой патологии – метастатического HER2-позитивного рака молочной железы у мужчины.

Об авторах

Е. В. Лубенникова
ФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России
Россия

Лубенникова Елена Владимировна, к. м. н., с. н. с. химиотерапевтического отделения № 11

Москва



М. В. Хорошилов
ФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России
Россия

Хорошилов Максим Викторович, врач-онколог химиотерапевтического отделения № 11

Москва



Н. Ц. Дробот
ФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России
Россия

Дробот Наталья Цырен-Дондоковна, к. м. н., врач-рентгенолог
рентгенодиагностического отделения

Москва



Е. В. Артамонова
ФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; ФУВ ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»
Россия

Артамонова Елена Владимировна, д. м. н., зав. химиотерапевтическим отделением № 11, ФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России; проф. кафедры онкологии и лучевой терапии, ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; зав. кафедрой онкологии и торакальной хирургии, ФУВ ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»

Москва



Список литературы

1. Slamon D.J., Leyland-Jones B., Shak S. et al Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783–792.

2. Swain S., Baselga J., Kim S. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015; 372: 724–734.

3. Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., … & Gianni, L. (2017). Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology, 2018; 6: 732–742.

4. Weigel M.T., Ghazoui Z., Dunbier A. et al. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Research. 2012; 14 (3): P. 78.

5. Ross J.S., Slodkowska E.A., Symmans W.F. et al. The HER-2 receptor and breast cancer: ten years of ttargeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009; 14 (4): 320–68.

6. Opdam F.L., Guchelaar H.J., Beijnen J.H., Schellens J.H. Lapatinib for advanced or metastatic breast cancer. The oncologist. 2012; 17 (4): 536–542.

7. Fleeman N., Bagust A., Boland A., Dickson R., Dundar Y., Moonan, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. NIHR Health Technology Assessment programme: Executive Summaries. 2011.

8. Gradishar W.J., Hegg R., Im S.A., Park I.H., Tjulandin S., Kenny S., et al. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+ AI vs L+ AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. 2017.

9. Arpino G., Haba-Rodriguez J., Ferrero J-M., De Placido S., Klingbiel D., Revelant V. et al. Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8–11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021; 81 (4 Suppl): Abstract Nr PD3–02.

10. Petrelli F., Barni S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clinical Breast Cancer, 2013; 2; 81–87.

11. Esteva F.J., Yu D., Hung M.C. et al. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature reviews Clinical oncology, 2010; 7 (2); 98–107.

12. von Minckwitz G., Schwedler K., Schmidt M., Barinoff J., Mundhenke C., Cufer T. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. European journal of cancer. 2011; 47 (15): 2273–2281.

13. Palle J., Tougeron D., Pozet A., Soularue E., Artru P., Leroy F., et al. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. Oncotarget, 2017; 8 (60): 101383.

14. Makiyama A., Sukawa Y., Kashiwada T., Kawada J., Hosokawa A., Horie Y., et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). Journal of Clinical Oncology; 2020; 38 (17): 1919–1927.

15. Metro G., Baglivo S., Moretti R., Bellezza G., Sidoni A., Roila F. Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review. Oncology and therapy. 2020; 8 (2): 341–3.

16. Heinemann V., Di Gioia D., Vehling-Kaiser U., Harich H.D., Heinrich B., Welt A., et al. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol. 2011; 22 (3): 603–608.

17. Fumoleau P., Delgado F.M., Delozier T., Monnier A., Gil Delgado M.A., Kerbrat P., et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993; 11 (7):1245–1252

18. Martin M., Ruiz A., Balil A., Garcнa-Mata J., Calvo L., Carrasco E., et al. Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007; 8 (3): 219–225.

19. Fumoleau P., Delgado D.M., Delozier T., Monnier A., Gil Delgado M.A., Kerbrat P. et al. Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol. 1993; 11 (7): 1245–1252.

20. García-Conde J., Lluch A., Martin M., Casado A., Gervasio H., De Oliveira C. et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994; 5 (9): 854–857.

21. Freyer G., Delozier T., Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35–40.

22. Amadori D., Koralewski P., Tekiela A., et al. Efficacy and safety of oral vinorelbine in first-line metastatic breast cancer. Eur J Cancer 2001; 37 (Suppl. 6) (abstract 713).

23. Trillet Lenoir V., Sommer H., Delozier T., et al. Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Cancer Supplements 2004; 2: 3 (abstract 279).

24. Pluschnig U., Bartsch R., Gampenrieder S., et al. Oral vinorelbine in metastatic breast cancer: the Vienna experience. Ann Oncol 2008; 19 (Suppl. 8) (abstract 160).

25. Blancas I., Morales S., Diaz N., et al. Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol 2010; 28: 15S (abstract 10090).

26. Mansour M., Haddad N. Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previously treated with adjuvant anthracyclines and/or taxanes. Proc 21st International Congress on Anti-Cancer Treatment, 2010 (abstract 627).

27. Addeo R., Faiola V., Montella L., et al. A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: aphase II trial. J Clin Oncol 2009; 27: 15S (abstract 1085).

28. Steger G.G. et al. Single-agent oral vinorelbine as first-line chemotherapy for endocrine-pretreated breast cancer with bone metastases and no visceral involvement: NORBREAST-228 Phase II Study. Clinical breast cancer. 2018; 1: e41–e47.

29. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18: 2241–2251.

30. Pegram M.D., Konecny G.E., O’Callaghan C., Beryt M., Pietras R., Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004; 96: 739–749.

31. Lee Y.R., Huh S.J., Lee D.H., Yoon H.H., Seol Y.M., Choi Y.J., et al. Phase II study of vinorelbine plus trastuzumab in HER2 overexpressing metastatic breast cancer pretreated with anthracyclines and taxanes. J Breast Cancer. 2011; 14 (2): 140–146. DOI: 10.4048/jbc.2011.14.2.14

32. Andersson M., Lidbrink E., Bjerre K. et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264–271. https://doi.org/10.1200/JCO.2010.30.821

33. Burstein H.J., Keshaviah A., Baron A.D., Hart R.D., Lambert-Falls R., Marcom P.K., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer. 2007; 110: 965–72.

34. Bernardo G., Palumbo R., Bernardo A., et al. Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: final results of an extended phase II trial. Eur J Cancer Supplements 2006; 6: 7 (abstract 168).

35. Bartsch R., Wenzel C., Altorjai G., et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007; 102 (3): 375–81.

36. Heinemann V., Di Gioia D., Vehling-Kaiser U., et al. A prospective, multicenter phase II study of oral and intravenous vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol. 2010. DOI: 10.1093/annonc/mdq409.

37. Illarramendi J., Blancas I., Bueso P., et al. Oral vinorelbine in combination with trastuzumab in metastatic breast cancer: data on efficacy, safety when administered in first- or second-line setting. J Clin Oncol 2010; 28: 15S (abstracte11508).

38. Perez E.A., Lopez-Vega J.M., Petit T. et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016; 18:126. https://doi.org/10.1186/s13058-016-0773-6

39. Andersson M., Lopez-Vega J.M., Petit T. et al. Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by vinorelbine: VELVET cohort 2 final results. Oncologist. 2017; 22: 1160–1168. https://doi.org/10.1634/theoncologist.2017-0079

40. Reinhorn, D., Kuchuk, I., Shochat, T., Nisenbaum, B., Sulkes, A., Hendler, D., … & Yerushalmi, R. Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment, 2021; 188 (2): 379–387.

41. Weiss J.R., Moysich K.B., Swede H. Cancer incidence in five continents. IARC Sci Publ. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 20–26.

42. Fentiman I.S., Fourquet A., Hortobagyi G.N. Male breast cancer. Lancet. 2006; 367: 595–604. 44.

43. Borner M., Scheithauer W., Twelves C., Maroun J., Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001; 6 (Suppl 4): 12–16.

44. Liu G., Franssen E., Fitch M., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5.

45. Findlay M., Von Minckwitz G., Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008; 19: 212–22.

46. James R., Barni S., Fischer von Weikerstahl L., et al. Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. Eur J Cancer Supplements 2009; 7: 2 (abstract 3612).

47. Bernardo G., Palumbo R., Bernardo A., Teragni C., Poggi G., Delmonte A., et al Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: final results of an extended phase II trial. Eur J Cancer Suppl. 2008; 6 (7): 175.

48. Addeo R., Faiola V., Montella L., et al. A novel metronomic schedule of oral vinorelbine for treatment of metastatic breast cancer in elderly patients: a phase II trial. J Clin Oncol. 2009; 27: 15S (abstr 1085).

49. Addeo R., Faiola V., Montella L., er al. Low-dose metronomic administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clinical breast cancer. 2010; 10 (4): 301–306.

50. De Iuliis F., Salerno G., Taglieri L., Lanza R., Scarpa S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015; 101: 30–5.


Рецензия

Для цитирования:


Лубенникова Е.В., Хорошилов М.В., Дробот Н.Ц., Артамонова Е.В. Применение пероральной формы винорелбина при метастатическом раке молочной железы – выбор в пользу качества жизни. Медицинский алфавит. 2022;(13):7-13. https://doi.org/10.33667/2078-5631-2022-13-7-13

For citation:


Lubennikova E.V., Khoroshilov M.V., Drobot N.C., Artamonova E.V. Use of peroral form of vinorelbine in metastatic breast cancer – choice in favor of quality of life. Medical alphabet. 2022;(13):7-13. (In Russ.) https://doi.org/10.33667/2078-5631-2022-13-7-13

Просмотров: 25


ISSN 2078-5631 (Print)